Scott E. McNeil, Ph.D.

Dr. McNeil serves as the Director of the Nanotechnology Characterization Laboratory (NCL) for Leidos Biomedical Research at the Frederick National Laboratory for Cancer Research, where he coordinates preclinical characterization of nanotech cancer therapeutics and diagnostics. At the NCL, Dr. McNeil leads a team of scientists responsible for testing candidate nanotech drugs and diagnostics, evaluating safety and efficacy, and assisting with product development — from discovery-level, through scale-up and into clinical trials. NCL has assisted in characterization and evaluation of nearly 400 nanotechnology products, several of which are now in human clinical trials.

Dr. McNeil is a member of several working groups on nanomedicine, environmental health and safety, and other nanotechnology issues. He is an invited speaker to numerous nanotechnology-related conferences and has several patents pending related to nanotechnology and biotechnology. He is also a Vice President of Leidos Biomedical Research. He received his bachelor’s degree in chemistry from Portland State University and his doctorate in cell biology from Oregon Health Sciences University.